DS Biopharma Names Leopoldo Zambeletti To Board
This article was originally published in Scrip
DS Biopharma, a privately held biopharmaceutical company, has appointed Leopoldo Zambeletti to its board as non-executive director. As an investment banker, Zambeletti led the European Health Investment team at JP Morgan after which he held the same position at Credit Suisse. Since 2013, Zambeletti has been an independent strategic advisor to life science companies and is also non-executive director of Nogra Pharma, Advanced Accelerator Applications, Faron Pharmaceuticals, Summit Therapeutics Plc., and is an advisor and co-founder to the US medtech company Qardio.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.